Special ArticleThe Utility of the National Alzheimer’s Coordinating Center’s Database for the Rapid Assessment of Evolving Neuropathologic ConditionsMock, Charles MD, PhD*; Teylan, Merilee MPH*; Beecham, Gary PhD†; Besser, Lilah PhD‡; Cairns, Nigel J. PhD, FRCPath§; Crary, John F. MD, PhD∥; Katsumata, Yuriko PhD¶; Nelson, Peter T. MD, PhD¶; Kukull, Walter PhD*Author Information *National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA †Miller School of Medicine, John P. Hussman Institute for Human Genomics, University of Miami, Miami ‡School of Urban and Regional Planning, Florida Atlantic University, Boca Raton, FL §College of Medicine and Health, University of Exeter, Exeter, UK ∥Neuropathology Brain Bank & Research Core, Departments of Pathology & Neuroscience, Ronald M. Loeb Center for Alzheimer’s Disease, Icahn School of Medicine at Mount Sinai, Friedman Brain Institute, New York, NY ¶Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY Supported by The United States Department of Defense (W81XWH-14-1-0399; PI John F. Crary, MD, PhD), NIH (R01AG054008 and R01NS095252; PI John F. Crary), R01 AG062695 (MPI: Gary Beecham, PhD, Thomas Montine MD). The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG062428-01 (PI James Leverenz, MD) P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P30 AG062421-01 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P30 AG062429-01 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD). J.F.C. received research support from Genetech/Roche in the past. The remaining authors declare no conflicts of interest. Reprints: Charles Mock, MD, PhD, National Alzheimer’s Coordinating Center, University of Washington, 4311 11th Ave NE #300, Seattle, WA 98105 (e-mail: email@example.com). Alzheimer Disease & Associated Disorders: April–June 2020 - Volume 34 - Issue 2 - p 105-111 doi: 10.1097/WAD.0000000000000380 Buy Metrics Abstract The field of dementia research is rapidly evolving, especially with regards to our understanding of the diversity of neuropathologic changes that underlie cognitive decline. Definitions and criteria for known conditions are being periodically revised and refined, and new findings are being made about neuropathologic features associated with dementia status. The database maintained by the National Alzheimer’s Coordinating Center (NACC) offer researchers a robust, rapid, and statistically well-powered method to evaluate the implications of newly identified neuropathologic conditions with regards to comorbidities, demographic associations, cognitive status, neuropsychologic tests, radiographic findings, and genetics. NACC data derive from dozens of excellent US Alzheimer disease research centers, which collectively follow thousands of research volunteers longitudinally. Many of the research participants are autopsied using state-of-the-art methods. In this article, we describe the NACC database and give examples of its use in evaluating recently revised neuropathologic diagnoses, including primary age-related tauopathy (PART), limbic predominant age-related TDP-43 encephalopathy (LATE), and the preclinical stage of Alzheimer disease neuropathologic change, based on the National Institute on Aging—Alzheimer’s Association consensus guidelines. The dementia research community is encouraged to make use of this readily available database as new neuropathologic changes are recognized and defined in this rapidly evolving field. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.